851916-44-4

Usage

Uses

Used in Pharmaceutical Industry:
Methyl 4-(2,5-dimethyl-1H-pyrrol-1-yl)cyclopent-2-ene-1-carboxylate is used as an intermediate in the synthesis of various pharmaceuticals for its unique structural and functional properties. It plays a crucial role in the development of new drugs and medicines.
Used in Agrochemical Industry:
Methyl 4-(2,5-dimethyl-1H-pyrrol-1-yl)cyclopent-2-ene-1-carboxylate is used as a building block in the synthesis of agrochemicals, contributing to the development of effective and innovative products for agricultural applications.
Used in Medical Research and Drug Discovery:
Methyl 4-(2,5-dimethyl-1H-pyrrol-1-yl)cyclopent-2-ene-1-carboxylate may have potential applications in the field of medical research and drug discovery due to its unique properties. It can be utilized in the exploration of new therapeutic agents and the advancement of medical science.
It is important to handle and use Methyl 4-(2,5-dimethyl-1H-pyrrol-1-yl)cyclopent-2-ene-1-carboxylate with caution, as it may pose health and environmental risks if not properly managed.

Upstream product

• 110-13-4 2,5-hexanedione 
• 426226-35-9 (+)-methyl (1R,4S)-4-aminocyclopent-2-ene-1-carboxylate hydrochloride 
• 123-54-6 acetylacetone 
• 79200-56-9 (-)-2-azabicyclo[2.2.1]hept-5-en-3-one 
• 152279-17-9 methyl 4-aminocyclopent-2-ene-1-carboxylate 

Downstream Products

• 851916-45-5 methyl (1S,4S)-4-(2,5-dimethyl-1H-pyrrol-1-yl)-1-isopropylcyclopent-2-ene-1-carboxylate 

Relevant academic research and scientific papers

CHEMOKING RECEPTOR ANTAGONISTS

Disclosed herein are chemokine receptor antagonists of formula (I) wherein G1, X1, X2, and X3 are as defined in the specification. Compositions comprising such compounds; and methods for treating conditions and disorders using such compounds and compositions are also described.

CHEMOKINE RECEPTOR ANTAGONISTS

Disclosed herein are chemokine receptor antagonists of formula (I) wherein R1, R2, and R3 are as defined in the specification. Compositions comprising such compounds; and methods for treating conditions and disorders using

CHEMOKINE RECEPTOR ANTAGONISTS

Disclosed herein are chemokine receptor antagonists of formula (I) wherein R1, R2, and R3 are as defined in the specification. Compositions comprising such compounds; and methods for treating conditions and disorders using

AMINOCYCLOPENTYL PYRIDOPYRAZINONE MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY

Compounds of Formula I and Formula II (wherein A, E, j, k, m, n, R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R15, R16, R17, R18, R19, R24, R25, R26, R27, R28, R29, R30, R31, R32, R33, R34, X, Y and Z are as defined herein) which are modulators of chemokine receptor activity and are useful in the prevention or treatment of certain inflammatory and immunoregulatory disorders and diseases, allergic diseases, atopic conditions including allergic rhinitis, dermatitis, conjunctivitis, and asthma, as well as autoimmune pathologies such as rheumatoid arthritis and atherosclerosis. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which chemokine receptors are involved.

CCR-2 ANTAGONIST SALT

The present invention provides an efficient synthesis for the preparation of ((1R,3S)-3-isopropyl-3-{[3-(trifluoromethyl)-7,8-dihydro-1,6-naphthyridin-6(5H)-yl]carbonyl}cyclopentyl)[(3S,4S)-3-m ethoxytetrahydro-2H-pyran-4-yl]amine and its succinate salt.

PROCESS FOR THE PREPARATION OF CCR-2 ANTAGONIST

The present invention provides an efficient synthesis for the preparation of ((1R,3S)-3-isopropyl-3- {[3-(trifluoromethyl)-7,8-dihydro-1,6-naphthyridin-6(5H)-yl]carbonyl} cyclopentyl)[(3S,4S)-3-m ethoxytetrahydro- 2H-pyran-4-yl]amine and its succinate sal